Cereno Scientific är verksamma inom bioteknik. Bolaget är specialiserade inom läkemedelsutveckling av vanliga och sällsynta kardiovaskulära sjukdomar. Den främsta läkemedelskandidaten utvecklas för behandling av den sällsynta sjukdomen pulmonell arteriell hypertension (PAH), samt för trombosindikationer.
Cereno Scientific AB,556890-4071 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, adress mm för Cereno Scientific AB
Cereno Scientific is a leading clinical stage biotech company within cardiovascular epigenetic modulation. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. Cereno Scientific develops innovative drugs for cardiovascular diseases, with a broadened focus on thrombosis and rare fibrosis-related cardiovascular diseases.Recently, the company’s lead candidate CS1 received Orphan Drug Designation from the FDA for the treatment of Pulmonary Arterial Hypertension. Cereno Scientific is accelerating the building of a platform of drug candidates in epigenetic modulation, by HDAC inhibition, for cardiovascular and rare diseases. On March 10, the company’s main candidate CS1 was approved for Orphan Drug Designation by the FDA for the treatment of Pulmonary Arterial Hypertension. Cereno Scientific is developing a platform of cardiovascular therapies in the new field of epigenetics based on HDAC inhibition.
Cereno Scientific is a leading clinical stage biotech company within cardiovascular epigenetic modulation. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. Cereno Scientific develops innovative drugs for cardiovascular diseases, with a broadened focus on thrombosis and rare fibrosis-related cardiovascular diseases.Recently, the company’s lead candidate CS1 received Orphan Drug Designation from the FDA for the treatment of Pulmonary Arterial Hypertension. Cereno Scientific is accelerating the building of a platform of drug candidates in epigenetic modulation, by HDAC inhibition, for cardiovascular and rare diseases. On March 10, the company’s main candidate CS1 was approved for Orphan Drug Designation by the FDA for the treatment of Pulmonary Arterial Hypertension.
InorbitTx and Cereno Scientific announce a licensing agreement for IOT032, now CS036, for cardiovascular diseases. Please read the full article on BioStock
Senaste nyheter om - Cereno Scientific, aktieanalys, kursutveckling och rapporter. Cereno Scientific komplett bolagsfakta & börsnyheter från Analysguiden. Cereno Scientific meddelade idag att ett optionsavtal har signerats med University of Michigan, USA, vilket ger exklusiva rättigheter till att utvärdera Senaste nytt om Cereno Scientific B aktie. Cereno Scientific B komplett bolagsfakta från DI.se.
Cereno Scientific Mangold Insight - Uppdragsanalys 2019-05-31 Innovativ kandidat kan stoppa blodproppar Mangold tar upp bevakningen av Cereno Scientific med en köprekommenda-tion och sätter riktkursen till 7,3 kronor på 12 månaders sikt. Cereno Scien-tific utvecklar läkemedelskandidaten CS1, en ny formulering av valproinsyra
Detta skedde efter forskningsframsteg med en ny trombosförebyggande behandlingsprincip på Wallenberglaboratoriet för Kardiovaskulär och Metabol Forskning vid Sahlgrenska akademin, Göteborgs Universitet. Bolaget har sin hemvist i Göteborg Cereno Scientific växer fram som ett ledande bolag inom epigenetisk modulering inom hjärt-kärlsjukdomar tack vare utvecklingen av CS1, ett läkemedel byggt på en omformulering av den effektiva HDAC (Histone DeACetylase) -hämmaren valproinsyra. Cereno Scientific erhåller rättigheter att inlicensera en preklinisk kandidat från University of Michigan genom ett optionsavtal 2021-03-12 12:30 · Cision Cereno Scientific obtains the right to inlicense a preclinical candidate from University of Michigan through an option agreement Göteborgsbaserade Cereno Scientific utvecklar en ny klass av läkemedel inom CVD med en epigenetisk moduleringsplattform. Tidigare i år tilldelade FDA Cereno Scientific orphan drug designation-status för deras ledande kandidat CS1 i pulmonell arteriell hypertension (PAH). BioStock har nu publicerat en nulägesanalys av Cereno Scientific. Cereno Scientific utvidgar sitt patentskydd till Japan 17 februari, 2021 Förra månaden meddelade Cereno Scientific att bolagets patentskydd stärkts för två patentfamiljer avseende CS1 i Kanada och i Ryssland. Cereno Scientific publicerar bokslutskommunikén för 2020 (1 januari - 31 december 2020) 25-02: Cereno Scientific publishes year-end report for 2020 (1 January - 31 December 2020) 17-02: BioStock: Cereno Scientific expands IPR protection to Japan: 17-02: BioStock: Cereno Scientific utvidgar sitt patentskydd till Japan Patentskyddet för Cereno Scientifics primära tillgång, CS1, stärktes nyligen genom att två olika patentfamiljer expanderades.
The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. Cereno Scientific is a leading clinical stage biotech company within cardiovascular epigenetic modulation. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. Cereno Scientific is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The
Cereno Scientific develops innovative medicines for cardiovascular and rare diseases related to fibrosis, thrombosis, inflammation and high blood pressure in the lung as well as systemically. Cereno Scientific is a leading clinical stage biotech company within cardiovascular epigenetic modulation. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications.
Gilead sciences news
Cereno Scien-tific utvecklar läkemedelskandidaten CS1, en ny formulering av valproinsyra ESC Congress 2019 together with World Congress of Cardiology VD Sten R. Sörensen och CMO Björn Dahlöf deltar vid ESC Congress 2019. Kontakta Sten R. Sörensen på +46 (0) 733 74 03 74 eller sten.sorensen@cerenoscientific.com för att boka ett möte. Läs mer om evenemanget här. Cereno Scientific AB söker styrelseledamot Pressmeddelanden • Maj 30, 2016 11:38 CEST.
2021-04-16
Cereno Scientific utvecklar ett nytt förebyggande läkemedel mot blodpropp som bygger på kroppens egen intelligenta propplösningsmekanism. Inför bolaget. Mangold rekommenderar Köp i Cereno Scientific med riktkurs 4,50 kronor på 12 månaders sikt.
Blandningar exempel
27 maj 2019 AKTIEANALYS. Cerenos läkemedelskandidat CS1 förebygger blodproppar. För att finansiera fas II-studier genomför bolaget just nu en
With the advent of atomic timekeeping and the International System In physical science, time is defined as a measurement, or as what the clock face read CPTAC employs two complementary scientific approaches, a "Targeting Genome to Proteome" (Targeting G2P) approach and a "Mapping Proteome to Genome" (Mapping P2G) approach, in order to address biological questions from data generated on a sa A scientific concept is a scientific theory or law that explains why and how a natural event or process occurs. Scientific concepts include mathematical fo A scientific concept is a scientific theory or law that explains why and how a natur A practical definition of creativity that can be used to massively improve your own creativity levels. David contributes to SME Pals, a blog aimed at helping startups and online businesses. I'll cut a long story short and start by presentin Scientific experiments have brought about some amazing discoveries. Visit HowStuffWorks to find great articles about scientific experiments. Advertisement Scientific experiments are a fun and exciting way to learn more about the wonderful w Examples of scientific management for organizing production include the assembly line at Henry Ford's automobile plants and using production schedules and Examples of scientific management for organizing production include the assembly line A hypothesis represents an educated guess about what you think will happen, based on your observations.